Novel Therapies for ANCA-associated Vasculitis

Area of Science:

• Rheumatology
• Immunology
• Internal Medicine

Background:

• Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are chronic autoimmune diseases requiring long-term management.
• Current treatments often involve high-dose glucocorticoids (GCs), leading to significant toxicity.
• Relapses remain common, posing a challenge in maintaining long-term remission.

Purpose of the Study:

• To review the latest evidence on treatment innovations in AAV management.
• To discuss future therapeutic prospects for AAV.
• To highlight strategies for reducing GC toxicity and improving patient outcomes.

Main Methods:

• Review of recent clinical trials and published studies on AAV treatments.
• Analysis of novel therapeutic agents and their efficacy and safety profiles.
• Evaluation of pathogenetic mechanisms informing new treatment strategies.

Main Results:

• Reduced-dose GC regimens demonstrate comparable efficacy and improved safety for induction and maintenance in severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
• Avacopan represents a novel, GC-sparing therapeutic option targeting complement activation.
• Plasma exchange was ineffective in preventing end-stage renal disease or mortality in severe cases.
• Combination therapy with rituximab (RTX) and cyclophosphamide (CYC) shows promise for life-threatening manifestations.
• Mepolizumab is effective for refractory eosinophilic granulomatosis with polyangiitis (EGPA).

Conclusions:

• A paradigm shift towards reduced GC use and novel therapies like avacopan is emerging in AAV management.
• Optimizing maintenance strategies, potentially with longer treatment durations, is crucial.
• Targeted therapies such as mepolizumab offer new hope for specific AAV subtypes like EGPA.